SK-MES-1 Xenograft Model Service for NSCLC

The SK-MES-1 xenograft model represents a well-characterized preclinical system for interrogating lung squamous cell carcinoma (LUSC), a molecularly distinct NSCLC subtype driven by FGFR1 and SOX2 amplifications, STAT3 activation, and intrinsic resistance to EGFR-targeted agents. Alfa Cytology provides comprehensive SK-MES-1 xenograft model services spanning authenticated cell banking, tumor establishment, compound administration, and multi-parameter endpoint analysis to generate reproducible, publication-quality data that advance your LUSC therapeutic pipeline from target validation to lead optimization.

Overview of SK-MES-1 Xenograft Model for NSCLC

The SK-MES-1 cell line was established from a primary lung squamous cell carcinoma and is classified as a moderately differentiated pulmonary squamous carcinoma with epithelial morphology. Genetically, this line exhibits focal amplifications in SOX2 and FGFR1—two of the most prevalent oncogenic drivers in LUSC—along with constitutive STAT3 activation and wild-type EGFR and KRAS status. Unlike lung adenocarcinoma models, SK-MES-1 lacks actionable EGFR mutations or ALK rearrangements, instead presenting a molecular landscape dominated by copy-number alterations and pathway dysregulations characteristic of the squamous subtype, which accounts for approximately 25–30% of all lung cancers. The line also retains squamous differentiation markers including cytokeratin 5/6 and p63, while remaining negative for TTF-1, thereby preserving histopathological fidelity relevant to translational research.

Fig 1. Lobaplatin inhibited proliferation of SK-MES-1 lung squamous cells in a dose- and time-dependent manner (CCK-8), reaching >70% inhibition at 31.6 μM by 72 hours, providing the in vitro rationale for its antitumor activity in the SK-MES-1 xenograft model. (Zhang, Hongming, et al., 2016)

In immunodeficient murine hosts, SK-MES-1 cells form reproducible subcutaneous tumors with high take rates and steady growth kinetics, typically becoming palpable within two weeks post-inoculation. The xenograft model has demonstrated robust responses to platinum-based chemotherapeutics including third-generation lobaplatin, as well as to FGFR1 inhibitors, PI3K/mTOR pathway blockers, Ras inhibitors, and STAT3-targeting strategies. Serial passaging of orthotopic SK-MES-1 xenografts has further yielded metastatic subclones that disseminate to adrenal glands and chest wall—sites characteristic of human LUSC metastasis—broadening the model's utility for studying disease progression. Endpoint tumor tissues support immunohistochemistry, Western blotting, RNA sequencing, and flow cytometric analysis, providing multi-layered mechanistic insights into drug response and resistance pathways.

Cell Line Information: SK-MES-1

SK-MES-1 is a human lung squamous cell carcinoma line with epithelial morphology and robust tumorigenicity in immunodeficient mice. The line carries hallmark molecular alterations of the LUSC subtype, including SOX2 and FGFR1 amplifications, constitutive STAT3 activation, and wild-type EGFR and KRAS status, while lacking actionable driver mutations typical of lung adenocarcinoma. The table below summarizes the key biological and technical attributes of the SK-MES-1 cell line.

Our Services

Alfa Cytology offers fully integrated SK-MES-1 xenograft model services customized to your preclinical LUSC research objectives. Our scientific team oversees every phase—from authenticated cell line expansion and mycoplasma screening to tumor inoculation, randomized cohort allocation, compound dosing, and comprehensive endpoint analysis—ensuring regulatory compliance, data traceability, and transparent reporting throughout your study.

Workflow of SK-MES-1 Xenograft Model Construction

Construction of the SK-MES-1 xenograft model follows a systematic, quality-assured workflow designed to ensure reproducible tumor growth, ethical compliance, and robust data generation. Each stage is executed under GLP-aligned standard operating procedures with full documentation and batch traceability from cell banking to final report delivery.

1. Cell Line Authentication and Expansion: SK-MES-1 cells are revived from authenticated cryopreserved master stocks and expanded under sterile conditions. Short tandem repeat (STR) profiling, mycoplasma testing, and viability assessment are performed to confirm identity and purity. FGFR1 and SOX2 amplification status is verified by FISH or qPCR prior to inoculation.
2. Animal Preparation and Cohort Randomization: Immunodeficient mice are quarantined and acclimated for a minimum of five days under controlled environmental conditions. Animals are randomized into vehicle and treatment groups based on body weight, with all protocols approved by the institutional animal care and use committee (IACUC).
3. Tumor Cell Inoculation: A suspension of 1–5 × 10⁶ SK-MES-1 cells in 100–200 µL of ice-cold PBS or PBS/Matrigel (1:1) is injected subcutaneously into the right flank of each mouse using a sterile 25-gauge needle. Orthotopic lung implantation is available upon request for studies requiring organ-specific tumor microenvironment or metastasis modeling.
4. Longitudinal Tumor Monitoring: Tumor dimensions are measured with digital calipers twice weekly beginning from the appearance of palpable masses. Tumor volume is calculated using the modified ellipsoid formula: length × (width)² / 2. Body weight and clinical observations are recorded concurrently to assess treatment tolerability.
5. Test Article Administration: Investigational compounds are administered according to the study-specific regimen via oral gavage, intraperitoneal, intravenous, or subcutaneous routes. Vehicle control groups receive the equivalent formulation without active agent. Combination arms and dose-escalation cohorts are configured as specified in the study protocol.
6. Endpoint Assessment and Tissue Collection: Mice are humanely euthanized upon reaching the predetermined endpoint—typically when tumor volume approaches 1,500 mm³ or at a fixed study duration. Tumors are excised, weighed, and subdivided for formalin-fixed paraffin-embedded (FFPE) histology, snap-frozen molecular analysis, and single-cell dissociation for flow cytometry.
7. Data Analysis and Study Reporting: Tumor growth curves, tumor growth inhibition (TGI) percentages, and statistical comparisons between treatment groups are generated using validated biostatistical platforms. A comprehensive study report including raw data, methodology, representative images, and mechanistic interpretation is delivered to the sponsor.

Fig 2. SK-MES-1 xenograft model construction workflow.

Case Study-SK-MES-1 Xenograft Model Development

In a recent preclinical program, the SK-MES-1 xenograft model was employed to evaluate the anti-tumor efficacy of a novel platinum analog in combination with an FGFR1 pathway inhibitor for lung squamous cell carcinoma. Following subcutaneous inoculation of SK-MES-1 cells into athymic nude mice, measurable tumors were established within 12 days with a take rate exceeding 90%. Animals were randomized into vehicle, monotherapy, and combination treatment arms once mean tumor volume reached approximately 150 mm³. Longitudinal monitoring revealed dose-dependent tumor growth inhibition across treatment cohorts, with the combination arm demonstrating superior suppression compared to either monotherapy alone. Endpoint pharmacodynamic analysis showed marked induction of apoptosis as assessed by TUNEL staining, alongside modulation of downstream STAT3 and FGFR1 signaling markers in tumor lysates from combination-treated animals. Histopathological examination confirmed preserved squamous differentiation with CK5/6 and p63 positivity, and treatment-associated reductions in tumor cell density were observed in responder groups. These preclinical findings supported the mechanistic rationale for advancing the combination regimen into subsequent development stages.

Why Choose Alfa Cytology?

Engaging Alfa Cytology for your SK-MES-1 xenograft studies grants access to a scientifically rigorous, operationally transparent preclinical platform. Our integrated service infrastructure is designed to deliver high-fidelity, actionable data within competitive timelines.

• Authenticated cell repositories with routine STR profiling, mycoplasma screening, and driver gene verification to ensure genetic fidelity and experimental reproducibility.
• Customizable study designs including subcutaneous, orthotopic, and metastatic model configurations tailored to your mechanistic and therapeutic questions.
• Real-time tumor growth tracking via digital calipers or optional non-invasive imaging modalities such as bioluminescence and micro-CT upon request.
• Comprehensive endpoint analysis spanning histopathology, immunohistochemistry (CK5/6, p63, TTF-1, Ki-67, PD-L1), Western blot, qPCR, RNA sequencing, and multiplex cytokine profiling.
• Dedicated project scientists providing weekly progress updates, direct raw data access, and regulatory-compliant documentation packages.
• Streamlined study execution with standard tumor establishment and treatment phases typically completed within 4–6 weeks from project initiation.

Contact Us

Ready to advance your lung squamous cell carcinoma research with a validated SK-MES-1 xenograft model? Reach out to the Alfa Cytology scientific team today to discuss your study design, receive a customized proposal, and discover how our preclinical expertise can accelerate your LUSC therapeutic development. Contact us now to schedule a consultation and move your program forward with confidence.

For research use only. Not intended for any clinical use.